(WASHINGTON, D.C.) – Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville released the below statement today following the U.S. Senate confirming the nomination of Dr. Martin Makary to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA) by a recorded vote of 56-44.
“CHPA congratulates Dr. Makary on his confirmation by the Senate today as FDA Commissioner. His leadership comes at a pivotal time for public health, with opportunities to advance self-care innovation, safety, and access to trusted over-the-counter (OTC) medicines, dietary supplements, and OTC medical devices.
“CHPA is committed to engaging with Dr. Makary and his team on continued implementation and reauthorization of the Over-the-Counter Monograph User Fee Program (OMUFA), optimizing FDA’s Additional Condition for Nonprescription Use (ACNU) final rule, and modernizing the regulations overseeing dietary supplements. We also hope to continue enhancing the Rx-to-OTC switch process and appreciate Dr. Makary for highlighting its benefits during his remarks in the Senate HELP Committee earlier this month as a pathway to help lower healthcare costs and empower consumers. By collaborating on these key initiatives, we can help safeguard and advance public health with a modern, science-based regulatory framework that benefits consumers and fosters a healthier America.”
